Earlier this week, Daiichi Sankyo announced that it has launched its biosimilar trastuzumab, trastuzumab BS, referencing Herceptin, in Japan.
Earlier this week, Daiichi Sankyo announced that it has launched its biosimilar trastuzumab, trastuzumab BS, referencing Herceptin, in Japan.
In 2016, Daiichi Sankyo and Amgen entered into an exclusive biosimilar commercialization agreement. Under the agreement, Daiichi Sankyo would be responsible for filing for marketing approval as well as the distribution and commercialization of 9 biosimilars in Japan, while Amgen took over the development and manufacturing responsibilities.
The biosimilar trastuzumab was approved by the Pharmaceuticals and Medical Devices Agency on September 21, 2018, and is indicated for intravenous drip infusions at 60 mg and 150 mg for the treatment of breast cancer with human epidermal receptor 2 (HER2) overexpression, and unresectable advanced or relapsed gastric cancer with HER2 overexpression.
This marks the first biosimilar product launched by Daiichi Sankyo. “The company expects that the product will provide patients and medical professionals with various options for cancer treatment,” according to a company statement.
To date, the European market has seen the launches of 3 biosimilar trastuzumab products, sold as Ontruzant, Herzuma, and Kanjinti. While the FDA approved the first and only US-licensed biosimilar trastuzumab—Ogivri—nearly 1 year ago, it has yet to enter the US market, and no launch date has been made publicly available by sponsor Mylan.
Herceptin, developed by drug maker Roche, earned the company nearly $7,028,00 globally in 2017, making the medicine Roche’s second top-selling product.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.